Latest PregLem SA Stories
Geneva, Switzerland, 19 August 2008 - PregLem SA, a Swiss biopharmaceutical company specialized in reproductive medicine, today announced the start of an international Phase III clinical trial program for PGL4001 (ulipristal) in symptomatic uterine myoma, a common benign solid tumor of the genital tract in women of reproductive age. PGL4001, an orally active, selective progesterone receptor modulator, was shown in a previous Phase II study to be well...
- Bad luck; misfortune.
- The smallest amount possible or the most worthless thing.